Imatinib for systemic mast-cell disease

A. Pardanani, M. Elliott, T. Reeder, C. Y. Li, E. J. Baxter, N. C.P. Cross, A. Tefferi

Research output: Contribution to journalArticle

215 Scopus citations

Abstract

Imatinib has shown to be effective against malignant disease driven by ckit. We prospectively treated 12 adults with symptomatic systemic mast-cell disease at a dose of either 100 mg or 400 mg per day. Of the ten patients who we could assess for response, five (50%) had a measurable response to the drug, four of whom had important mast-cell cytoreduction and two who had complete clinical and histological remission. In the five patients with eosinophilia, three had complete clinical and haematological remission. The other two, who did not respond to treatment, were the only patients with the ckit D816V mutation. Our results suggest that imatinib either inhibits the growth-promoting role of wild type ckit, or targets an oncogenic kinase.

Original languageEnglish (US)
Pages (from-to)535-537
Number of pages3
JournalLancet
Volume362
Issue number9383
DOIs
StatePublished - Aug 16 2003

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Imatinib for systemic mast-cell disease'. Together they form a unique fingerprint.

  • Cite this

    Pardanani, A., Elliott, M., Reeder, T., Li, C. Y., Baxter, E. J., Cross, N. C. P., & Tefferi, A. (2003). Imatinib for systemic mast-cell disease. Lancet, 362(9383), 535-537. https://doi.org/10.1016/S0140-6736(03)14115-3